# TELA Bio (TELA) Stock Price, News & Analysis
Canonical URL: https://biopharmsignal.com/company/TELA
## Company Profile
- Ticker: TELA
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
## Stock Data
- Close: 0.86 USD
- Market cap: 40737192.86 USD
- Last updated: 2026-08-06
## Business Overview
### Soft-Tissue Reconstruction Company
TELA Bio develops medical devices for hernia repair, abdominal-wall reconstruction, and plastic and reconstructive surgery.
### Reinforced Tissue Matrices
The OviTex portfolio combines biologic tissue with polymer reinforcement to provide strength while supporting tissue remodeling.
### Commercial Surgical Model
TELA sells through a specialized surgical sales force and is expanding internationally as additional surgeons adopt its tissue-reconstruction products.
## Why The Stock Is Moving

Following the latest company update, “TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)”, TELA closed down 6.01% at $0.8600 on Aug 6, 2026. The move occurred in the trading session associated with this commercial update.

## Future Catalysts

- TELA Bio's story is really about the OviTex portfolio. OviTex PRS is still the core reconstruction product, while OviTex Inguinal and OviTex LPR give the company more specific ways to build around hernia repair and broader soft-tissue reconstruction. The next question is whether that portfolio keeps gaining surgeon adoption enough to feel embedded in routine practice.

## Recent News
- 2026-08-05 20:05 EST — [TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/TELA/tela-bio-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-7e98165f) — Source: TELA Bio
- 2026-08-04 11:00 EST — [TELA Bio Announces Appointment of Heather Getz as Chief Executive Officer and Director](https://biopharmsignal.com/news/TELA/tela-bio-announces-appointment-of-heather-getz-as-chief-executive-officer-and-di-172ffd1d) — Source: TELA Bio
- 2026-07-29 20:05 EST — [TELA Bio to Participate in the Canaccord Genuity 46th Annual Growth Conference](https://biopharmsignal.com/news/TELA/tela-bio-to-participate-in-the-canaccord-genuity-46th-annual-growth-conference-0473c6fd) — Source: TELA Bio
- 2026-07-20 20:05 EST — [TELA Bio to Announce Second Quarter 2026 Financial Results](https://biopharmsignal.com/news/TELA/tela-bio-to-announce-second-quarter-2026-financial-results-d696973e) — Source: TELA Bio
- 2026-05-12 20:05 EST — [TELA Bio Reports First Quarter 2026 Financial Results](https://biopharmsignal.com/news/TELA/tela-bio-reports-first-quarter-2026-financial-results) — Source: TELA Bio